Key highlights
27 April 2023 – 1 mins read
LinkedIn
Twitter
Facebook
Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance
Paris (France), 27 April 2023
Filter
Period
Filter by
recent search
Showing: 1 – 05 of 22 Financial Results
02 May 2024
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
PARIS, FRANCE, 24 April 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024.
24 April 2024
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
PARIS, FRANCE, 24 April 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024.
08 February 2024
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
PARIS, FRANCE, 8 February 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the year and final quarter of 2023.
26 October 2023
Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance
Paris (France), 26 October 2023
27 July 2023
Ipsen delivers solid H1 2023 results and upgrades its full-year guidance
Paris, France: 27 July 2023Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, presents today its financial results for the first half of 2023.
Your dedicated contacts
-
Craig Marks
Vice President, Investor Relations
-
-
Nicolas Bogler
Senior Manager, Investor Relations
-